<DOC>
	<DOCNO>NCT00070135</DOCNO>
	<brief_summary>This phase II trial study well fludarabine busulfan follow donor ( allogeneic ) stem cell transplant work treat old patient acute myeloid leukemia first complete remission . Giving low dos chemotherapy , fludarabine busulfan , donor peripheral blood stem cell transplant help stop growth cell bone marrow , include normal blood-forming cell ( stem cell ) cancer cell . It may also stop patient 's immune system reject donor 's stem cell . When healthy stem cell donor infused patient may help patient 's bone marrow make stem cell , red blood cell , white blood cell , platelet . The donated stem cell may replace patient 's immune system help destroy remain cancer cell . Sometimes transplanted cell donor make immune response body 's normal cell ( call graft-versus-host disease ) . Giving tacrolimus , methotrexate , rabbit antithymocyte globulin transplant may stop happening .</brief_summary>
	<brief_title>Fludarabine Busulfan Followed Allogeneic Stem Cell Transplant Treating Older Patients With Acute Myeloid Leukemia First Complete Remission</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . Determine allogeneic transplantation match sibling unrelated donor use non-myeloablative preparative regimen result 2-year disease-free survival ( DFS ) well historical result use standard chemotherapy . SECONDARY OBJECTIVES : I . Determine 2-year actuarial risk transplant-related mortality , acute chronic graft-versus-host ( GVHD ) disease relapse among patient acute myeloid leukemia ( AML ) first complete remission ( CR1 ) follow non-myeloablative preparative regimen . II . To examine recovery T B cell number function follow non-myeloablative stem cell transplant . III . To examine time course T , B myeloid progenitor chimerism follow preparative regimen . IV . To characterize pharmacokinetics intravenous busulfan use non-myeloablative preparation regimen AML patient age &gt; = 60 year . OUTLINE : PREPARATIVE REGIMEN : Patients receive fludarabine intravenously ( IV ) 30 minute day -7 -3 busulfan IV 2 hour 4 time per day ( every 6 hour ) day -4 -3 . GRAFT-VERSUS-HOST DISEASE ( GVHD ) PROPHYLAXIS : Patients receive tacrolimus orally ( PO ) IV twice daily ( BID ) day -2 taper day 90-120 , stop day 150-180 . Patients also receive methotrexate IV day 1 , 3 , 6 , 11 rabbit antithymocyte globulin IV 4-6 hour day -4 -2 . ALLOGENEIC PERIPHERAL BLOOD STEM CELL TRASNPLANTATION ( PBSC ) : Patients undergo allogeneic PBSC transplant day 0 . Patients receive filgrastim subcutaneously ( SC ) daily begin day 12 continue blood count recover . Patients follow monthly 1 year , every 3 month 1 year , every 6 month 3 year .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Tacrolimus</mesh_term>
	<mesh_term>Antilymphocyte Serum</mesh_term>
	<mesh_term>Busulfan</mesh_term>
	<mesh_term>Vidarabine</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Lenograstim</mesh_term>
	<criteria>Eligibility Criteria : Patients acute myeloid leukemia ( AML ) ( exclude FrenchAmericanBritish [ FAB ] classification system M3 ) achieve first morphologic complete remission meet criterion ; patient precede myelodysplastic syndrome ( MDS ) treatmentrelated AML eligible ; patient prior central nervous system ( CNS ) involvement eligible long disease remission transplant ; patient acute leukemia follow blast transformation prior chronic myeloid leukemia ( CML ) myeloproliferative disease exclude Complete remission ( CR ) define accord revise recommendation International Working Group ( 24 ) following : Normal bone marrow morphology &lt; 5 % blast Absolute neutrophil count ( ANC ) &gt; 1,000/uL , refer count need confirm patient achieve CR Platelet count &gt; 100,000/uL No extramedullary leukemia No blast peripheral blood CR achieve one two ( two ) cycle induction chemotherapy standard cytotoxic chemotherapy ( e.g. , cytarabine anthracycline ) four cycle hypomethylating agent contain regimen include either 5azacytidine decitabine Patients may receive many two cycle consolidation therapy prior transplant ; consolidation regimen require transplant use ; 6 month elapse documentation morphologic CR transplant ; platelet count need &gt; 100,000/uL consolidation , long bone marrow assessment prior transplant show relapse Identification hematopoietic cell donor &gt; = 4 week since prior chemotherapy , radiation therapy , surgery Performance status 02 Diffusion capacity carbon monoxide ( DLCO ) &gt; 40 % symptomatic pulmonary disease Left ventricular ejection fraction ( LVEF ) multi gate acquisition scan ( MUGA ) echocardiogram ( ECHO ) &gt; = 30 % No uncontrolled diabetes mellitus active serious infection require antibiotic No know hypersensitivity E. coliderived product No human immunodeficiency virus ( HIV ) infection Calculated creatinine clearance &gt; = 40 cc/min Bilirubin &lt; 2 mg/dL * If bilirubin 23 mg/dL , direct bilirubin normal patient consider eligible Aspartate aminotransferase ( AST ) &lt; 3 x upper limit normal DONOR : HLAidentical sibling ( 6/6 ) ; donor must determine human leukocyte antigen ( HLA ) identical sibling ( 6/6 ) serologic type class ( A , B ) low resolution molecular type class II ( DRB1 ) DONOR : Matched unrelated donor ( 10/10 ) ; high resolution molecular typing follow locus require : HLAA , B , C , DRB1 , DQB1 DONOR : donor must healthy must acceptable donor per institutional standard stem cell donation DONOR : donor must significant cardiopulmonary , renal , endocrine , hepatic disease DONOR : donor age restriction donor match sibling DONOR : syngeneic donor eligible</criteria>
	<gender>All</gender>
	<minimum_age>60 Years</minimum_age>
	<maximum_age>74 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>adult acute myeloid leukemia remission</keyword>
	<keyword>secondary acute myeloid leukemia</keyword>
	<keyword>adult acute monocytic leukemia ( M5b )</keyword>
	<keyword>adult acute erythroid leukemia ( M6 )</keyword>
	<keyword>adult acute megakaryoblastic leukemia ( M7 )</keyword>
	<keyword>adult acute minimally differentiate myeloid leukemia ( M0 )</keyword>
	<keyword>adult acute myeloblastic leukemia maturation ( M2 )</keyword>
	<keyword>adult acute myeloblastic leukemia without maturation ( M1 )</keyword>
	<keyword>adult acute myelomonocytic leukemia ( M4 )</keyword>
	<keyword>adult acute monoblastic leukemia ( M5a )</keyword>
	<keyword>adult acute myeloid leukemia ( 8 ; 21 ) ( q22 ; q22 )</keyword>
	<keyword>adult acute myeloid leukemia ( 16 ; 16 ) ( p13 ; q22 )</keyword>
	<keyword>adult acute myeloid leukemia inv ( 16 ) ( p13 ; q22 )</keyword>
	<keyword>adult acute myeloid leukemia 11q23 ( MLL ) abnormality</keyword>
</DOC>